Sensei Biotherapeutics Files Q1 2025 10-Q
Ticker: SNSE · Form: 10-Q · Filed: May 6, 2025 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Sensei Bio's Q1 2025 10-Q is in: financials updated, check for cash burn and runway.
AI Summary
Sensei Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data includes changes in additional paid-in capital and various expense categories, alongside information on marketable securities and common stock.
Why It Matters
This filing provides investors with the latest financial health and operational status of Sensei Biotherapeutics, crucial for understanding its ongoing development and market position.
Risk Assessment
Risk Level: medium — As a biotherapeutics company, Sensei Biotherapeutics is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the specific quarter the financial data pertains to.)
- 20250506 — Filing Date (Shows when the company submitted its quarterly report to the SEC.)
- 2024-03-31 — Prior Year Q1 End Date (Provides a comparative point for year-over-year analysis.)
- 2024-12-31 — Prior Year End Date (Used for comparing year-end financial positions.)
- 2023-12-31 — Previous Year End Date (Offers a longer-term perspective on financial trends.)
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250506 (date) — Date of filing
- 2834 (dollar_amount) — Standard Industrial Classification code for Pharmaceutical Preparations
- DE (company) — State of incorporation
- 1231 (date) — Fiscal year end
- 1934 Act (company) — Securities Exchange Act of 1934
- 001-39980 (dollar_amount) — SEC File Number
FAQ
What was Sensei Biotherapeutics' net loss for the first quarter of 2025?
The provided text does not explicitly state the net loss for Q1 2025. It focuses on financial statement line items and dates.
How much cash and cash equivalents did Sensei Biotherapeutics have as of March 31, 2025?
The filing excerpt does not specify the exact amount of cash and cash equivalents as of March 31, 2025.
What were the total operating expenses for the three months ended March 31, 2025?
Specific figures for total operating expenses for the period are not detailed in this excerpt.
Did Sensei Biotherapeutics engage in any equity or debt fundraising events in the first quarter of 2025?
The filing mentions equity and debt fundraising events for the period of January 1, 2024 to December 31, 2024, but not specifically for Q1 2025.
What is the company's primary business activity according to the SIC code?
The company's primary business activity is classified under Pharmaceutical Preparations, indicated by the SIC code 2834.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Sensei Biotherapeutics, Inc. (SNSE).